Rigel Pharma to focus on three leading clinical programs

5 September 2013

USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) today announced its plans to focus the company's resources on the completion of three lead clinical programs, a move which follows recent disappointing clinical results with the company’s asthma drug candidate R343 (The Pharma Letter August 27).

These efforts include commencing a Phase III clinical study of fostamatinib (previously licensed to AstraZeneca, which has returned rights to the drug; TPL June 4), an oral SYK inhibitor, in immune thrombocytopenic purpura (ITP) pending discussions with regulatory agencies. Rigel believes that a Phase III clinical program would encompass around 150 patients and can be completed in 2015.

Rigel's other two lead programs, R333, a topical dermatological JAK/SYK inhibitor for discoid lupus erythematosus, and R348, a topical ophthalmic JAK/SYK inhibitor for dry eye, are presently in Phase II studies, with results expected in fourth-quarter 2013 and second-quarter 2014, respectively. Rigel expects to advance one of these two molecules into a Phase III clinical program by 2014/15.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK